Hematology

Biology, Genetics, and the Search for Answers

At a Glance

CDA IV is a rare genetic anemia usually caused by the KLF1 E325K change, which disrupts red blood cell maturation and can cause early red blood cell breakdown and severe anemia. Genetic testing must show a pathogenic or likely pathogenic KLF1 variant; a VUS does not confirm the diagnosis.

The biological cause of Congenital Dyserythropoietic Anemia Type IV (CDA IV) lies in a single genetic instruction that has changed. Understanding how this change affects the body can help you navigate the diagnostic process and the road ahead.

The Role of KLF1: The “Master Switch”

Every red blood cell starts as a “progenitor” cell in the bone marrow. To become a functional red blood cell that carries oxygen, it must go through a complex series of steps, including maturing, changing shape, and eventually ejecting its nucleus (the cell’s control center) ^[1].

A gene called KLF1 acts as a master switch (a transcription factor) that helps regulate many other erythroid genes ^[2]. By turning these genes on or off, KLF1 impacts:

Terminal Differentiation: The final maturation steps before a cell enters the bloodstream ^[1].
Cytokinesis: The process of cell division. When this is disrupted, cells may fail to divide correctly, leading to multinucleated cells (cells with more than one nucleus) ^[3]^[4].
Globin Switching: Transitioning from producing fetal hemoglobin (HbF) to adult hemoglobin (HbA) ^[5].

The E325K Mutation

Most reported cases of CDA IV are caused by a specific mutation in the KLF1 gene known as E325K ^[2].

Experimental studies suggest that the E325K mutation alters the shape of the protein that binds to DNA ^[6]. Instead of binding to its normal targets, the altered protein may bind to wrong sites, disrupting the normal regulation of cell maturation ^[7]. This leads to a situation where red blood cells cannot mature properly, are shaped incorrectly, and break down too easily (hemolysis) ^[8]^[9]. While high HbF is a major hallmark of this process, it does not reliably predict the severity of the disease or guarantee protection from severe anemia ^[10]. Genetic testing confirms the diagnosis ^[11].

Genetics and Inheritance

CDA IV is an autosomal dominant condition, meaning only one copy of a pathogenic mutated gene is needed to cause the disease ^[6].

However, in almost every reported case of the E325K mutation, the mutation is de novo ^[2]. This means it happened for the first time in the affected individual—it was not inherited from either parent.

For the Parents: If blood tests show neither parent carries the mutation, the risk of having another child with CDA IV is generally low ^[12]. However, because of a rare phenomenon called mosaicism (where the mutation might be present in a parent’s reproductive cells but not their blood), a genetic counselor can help individualize the recurrence risk ^[13].
For the Patient: If a person with a confirmed heterozygous pathogenic germline E325K variant has children, there is a 50% chance of passing the mutation to each child.

Note: A laboratory finding of a “Variant of Uncertain Significance” (VUS) in the KLF1 gene is not proof of CDA IV. The variant must be classified as pathogenic or likely pathogenic and fit the clinical picture.

What CDA IV Is Not: The Challenge of Diagnosis

Because CDA IV is ultra-rare, its symptoms overlap heavily with other congenital anemias. Specialist interpretation of genetic and clinical findings is required.

Condition	Why it might overlap	How it differs
Thalassemia	Both can involve abnormal red cell sizes and high HbF ^[14].	Thalassemia is caused by mutations in the globin genes themselves, not the KLF1 gene ^[15].
HPFH (Hereditary Persistence of Fetal Hemoglobin)	Both have very high levels of HbF ^[2].	HPFH is usually a benign condition; people with it lack the severe anemia and ineffective erythropoiesis seen in CDA IV ^[16].
CDA Types I & II	All CDAs show abnormal bone marrow cells ^[17].	Types I and II are caused by different genes (e.g., CDAN1, CDIN1, SEC23B) and have different morphological clues ^[18].
Diamond-Blackfan Anemia	Both are severe congenital anemias ^[12].	DBA is characterized by marked erythroid hypoplasia (a severe lack of red blood cell precursors), unlike the overactive but ineffective marrow in CDA IV ^[19].
Pyruvate Kinase Deficiency	Both involve rapid red cell breakdown (hemolysis) ^[20].	PK deficiency is an enzyme defect and does not ordinarily produce the classic multinucleated marrow pattern seen in CDA IV ^[21].

Common questions in this guide

What gene is most often responsible for CDA IV?

Most reported cases of CDA IV are linked to the E325K change in the KLF1 gene. KLF1 helps turn on genes needed for red blood cell maturation, so this change can lead to abnormal development and early breakdown of red blood cells.

Is CDA IV passed down from a parent?

CDA IV follows an autosomal dominant pattern, meaning one disease-causing KLF1 copy can cause the condition. However, the E325K change has usually arisen de novo, so it is often not found in either parent; a genetic counselor can discuss the small residual chance from mosaicism.

Can someone with CDA IV pass it to a child?

Yes. If a person has a confirmed disease-causing KLF1 variant in one copy of the gene, each child has a 50% chance of inheriting it. A genetic counselor can explain testing and family-planning options.

Does high fetal hemoglobin mean CDA IV will be mild?

No. High fetal hemoglobin, or HbF, is a common hallmark of CDA IV, but its level does not reliably predict how severe the anemia will be or guarantee protection from severe anemia. Doctors interpret HbF alongside symptoms, blood tests, and genetic findings.

Does a KLF1 variant of uncertain significance confirm CDA IV?

No. A variant of uncertain significance, or VUS, is a genetic finding whose meaning is not yet clear and does not by itself confirm CDA IV. The variant generally needs to be classified as pathogenic or likely pathogenic and match the clinical picture.

How is CDA IV distinguished from other congenital anemias?

Doctors combine clinical findings, blood and bone marrow features, and genetic testing. CDA IV is associated with a KLF1 variant, while thalassemia involves globin genes, HPFH is usually benign, and other congenital anemias have different genetic or marrow patterns.

Get notified when new evidence is published on Congenital dyserythropoietic anemia type IV.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (21)

1
KLF1 coordinates specialized transcriptional networks required to maintain the integrity of terminal erythropoiesis.
Gnanapragasam MN, Jiang P, Dhara AR, et al.
Journal of cell science 2025; (138(21)) doi:10.1242/jcs.264036.
PMID: 40977284
2
Erythroid Krüppel-Like Factor (KLF1): A Surprisingly Versatile Regulator of Erythroid Differentiation.
Bieker JJ, Philipsen S
Advances in experimental medicine and biology 2024; (1459()):217-242 doi:10.1007/978-3-031-62731-6_10.
PMID: 39017846
3
KLF1 mutation E325K induces cell cycle arrest in erythroid cells differentiated from congenital dyserythropoietic anemia patient-specific induced pluripotent stem cells.
Kohara H, Utsugisawa T, Sakamoto C, et al.
Experimental hematology 2019; (73()):25-37.e8 doi:10.1016/j.exphem.2019.03.001.
PMID: 30876823
4
A novel human cellular model of CDA IV enables comprehensive analysis revealing the molecular basis of the disease phenotype.
Ferrer-Vicens I, Ferguson DCJ, Wilson MC, et al.
Blood 2023; (141(25)):3039-3054 doi:10.1182/blood.2022018735.
PMID: 37084386
5
Can mutations in the gene encoding transcription factor EKLF (Erythroid Krüppel-Like Factor) protect us against infectious and parasitic diseases?
Mikołajczyk K, Kaczmarek R, Czerwiński M
Postepy higieny i medycyny doswiadczalnej (Online) 2016; (70(0)):1068-1086 doi:10.5604/17322693.1221384.
PMID: 27708211
6
Corrupted DNA-binding specificity and ectopic transcription underpin dominant neomorphic mutations in KLF/SP transcription factors.
Ilsley MD, Huang S, Magor GW, et al.
BMC genomics 2019; (20(1)):417 doi:10.1186/s12864-019-5805-z.
PMID: 31126231
7
A Krüppel-like factor 1 (KLF1) Mutation Associated with Severe Congenital Dyserythropoietic Anemia Alters Its DNA-Binding Specificity.
Kulczynska K, Bieker JJ, Siatecka M
Molecular and cellular biology 2020; (40(5)) doi:10.1128/MCB.00444-19.
PMID: 31818881
8
Genetic disarray follows mutant KLF1-E325K expression in a congenital dyserythropoietic anemia patient.
Varricchio L, Planutis A, Manwani D, et al.
Haematologica 2019; (104(12)):2372-2380 doi:10.3324/haematol.2018.209858.
PMID: 30872368
9
Hemoglobin switching in mice carrying the Klf1 variant.
Korporaal A, Gillemans N, Heshusius S, et al.
Haematologica 2021; (106(2)):464-473 doi:10.3324/haematol.2019.239830.
PMID: 32467144
10
KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome.
Magor GW, Tallack MR, Gillinder KR, et al.
Blood 2015; (125(15)):2405-17 doi:10.1182/blood-2014-08-590968.
PMID: 25724378
11
Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia.
Hamada M, Doisaki S, Okuno Y, et al.
International journal of hematology 2018; (108(3)):306-311 doi:10.1007/s12185-018-2482-7.
PMID: 29936674
12
Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias.
Shefer Averbuch N, Steinberg-Shemer O, Dgany O, et al.
European journal of haematology 2018; (101(3)):297-304 doi:10.1111/ejh.13097.
PMID: 29786897
13
Low frequency of parental mosaicism in de novo COL4A5 mutations in X-linked Alport syndrome.
Helle OMB, Pedersen TH, Ousager LB, et al.
Molecular genetics & genomic medicine 2020; (8(10)):e1452 doi:10.1002/mgg3.1452.
PMID: 32812400
14
KLF1 mutation-associated congenital dyserythropoietic anemia type IV: a case report and literature review.
Lu K, He Y, Nong S, et al.
Frontiers in pediatrics 2026; (14()):1854766 doi:10.3389/fped.2026.1854766.
PMID: 42597595
15
New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia.
D'Alcamo E, Agrigento V, Pitrolo L, et al.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2016; (32(Suppl 1)):278-81 doi:10.1007/s12288-015-0633-z.
PMID: 27408412
16
Krüppel-like factor 1: hematologic phenotypes associated with KLF1 gene mutations.
Waye JS, Eng B
International journal of laboratory hematology 2015; (37 Suppl 1()):78-84 doi:10.1111/ijlh.12356.
PMID: 25976964
17
Congenital dyserythropoietic anaemia type II in a teenager presenting with severe anaemia.
Pinto CJ, Narayanaswamy MH, Khatawkar AV, Poornima J
BMJ case reports 2023; (16(2)) doi:10.1136/bcr-2022-251756.
PMID: 36750299
18
Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients.
Marra R, Nostroso A, Rosato BE, et al.
American journal of hematology 2024; (99(8)):1511-1522 doi:10.1002/ajh.27350.
PMID: 38666530
19
[Differential diagnosis of inherited bone marrow failure syndromes in erythrocyte disorders].
Hama A
[Rinsho ketsueki] The Japanese journal of clinical hematology 2022; (63(6)):590-599 doi:10.11406/rinketsu.63.590.
PMID: 35831193
20
Pyruvate kinase deficiency mimicking congenital dyserythropoietic anemia type I.
Yozgat AK, Erdem AY, Kaçar D, et al.
The Turkish journal of pediatrics 2022; (64(5)):951-955.
PMID: 36305449
21
Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias.
Russo R, Andolfo I, Manna F, et al.
American journal of hematology 2018; (93(5)):672-682 doi:10.1002/ajh.25058.
PMID: 29396846

This page explains CDA IV biology, KLF1 testing, and inheritance for educational purposes; it does not replace medical advice. A hematologist and genetic counselor should interpret your results and discuss family-planning risk.